Expertise in
2
conditions

Dr. James Bailen

Urology
First Urology PSC
101 Hospital Blvd, 
Jeffersonville, IN 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
2
conditions
First Urology PSC
101 Hospital Blvd, 
Jeffersonville, IN 

Overview

James Bailen is a Urologist practicing medicine in Jeffersonville, Indiana.

Dr. Bailen is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Bladder Cancer, and Enlarged Prostate (BPH).

He is actively involved in clinical research, co-authoring 14 peer reviewed articles and participating in 11 clinical trials.

Specialties

Urology

Licenses

Urology in KY

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

First Urology PSC
101 Hospital Blvd, Jeffersonville, IN 47130

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Phase 1, Open-Label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer
Phase 1, Open-Label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer
Enrollment Status: Recruiting
Publish Date: February 04, 2026
Intervention Type: Drug
Study Drug: Abiraterone Decanoate
Study Phase: Phase 1
A Randomized, Controlled, Open-Label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients With Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
A Randomized, Controlled, Open-Label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients With Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
Enrollment Status: Terminated
Publish Date: June 06, 2024
Intervention Type: Drug, Procedure
Study Drug: Mitomycin C
Study Phase: Phase 3
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
Enrollment Status: Terminated
Publish Date: February 05, 2024
Intervention Type: Drug
Study Drugs: VERU-111, Enzalutamide, Abiraterone, Darolutamide and Apalutamide
Study Phase: Phase 3
Phase 3 Study Investigating the Efficacy and Safety of TAVT-45 (Abiraterone Acetate) Granules for Oral Suspension (Novel Abiraterone Acetate Formulation) Relative to a Reference Abiraterone Acetate Formulation in Patients With mCSPC & mCRPC
Phase 3 Study Investigating the Efficacy and Safety of TAVT-45 (Abiraterone Acetate) Granules for Oral Suspension (Novel Abiraterone Acetate Formulation) Relative to a Reference Abiraterone Acetate Formulation in Patients With mCSPC & mCRPC
Enrollment Status: Completed
Publish Date: January 16, 2024
Intervention Type: Drug
Study Drugs: TAVT-45, Zytiga, Prednisone
Study Phase: Phase 3
Open-Label, Proof-of-Concept and Dose Finding Phase 1b/2 Study of VERU-100 in Men With Advanced Prostate Cancer
Open-Label, Proof-of-Concept and Dose Finding Phase 1b/2 Study of VERU-100 in Men With Advanced Prostate Cancer
Enrollment Status: Terminated
Publish Date: May 19, 2023
Intervention Type: Drug
Study Drug: VERU-100
Study Phase: Phase 1/Phase 2
A Pilot Multicenter, Randomized, Double-Blind Study Comparing The Proportion Of Responders to PSD502 and to Placebo Using the PEBEQ In Subjects With Premature Ejaculation
A Pilot Multicenter, Randomized, Double-Blind Study Comparing The Proportion Of Responders to PSD502 and to Placebo Using the PEBEQ In Subjects With Premature Ejaculation
Enrollment Status: Completed
Publish Date: July 05, 2022
Intervention Type: Drug
Study Drug: PSD502
Study Phase: Phase 2
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Single Arm Study for the Treatment of BPH in Large Prostates (Rezūm XL)
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Single Arm Study for the Treatment of BPH in Large Prostates (Rezūm XL)
Enrollment Status: Terminated
Publish Date: August 10, 2021
Intervention Type: Device
Study Phase: Not Applicable
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: May 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer
A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer
Enrollment Status: Terminated
Publish Date: August 28, 2019
Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
Enrollment Status: Terminated
Publish Date: August 19, 2019
Intervention Type: Biological
View 9 Less Clinical Trials

14 Total Publications

Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points.
Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points.
Journal: The Journal of urology
Published: December 05, 2025
Similar Doctors
Expertise in
53
conditions
Expertise in
53
conditions
Referral may be required

First Urology PSC

101 Hospital Blvd, 
Jeffersonville, IN 
 (0.1 miles away)
812-282-3899
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Rosenbaum is a Urologist practicing medicine in Jeffersonville, Indiana. Dr. Rosenbaum is highly rated in 53 conditions, according to our data. His clinical expertise encompasses Ureterocele, Kidney Stones, Perirenal Abscess, Ureteroscopy, and Reconstructive Urology Surgery.

Expertise in
52
conditions
Expertise in
52
conditions
Referral may be required

First Urology, PSC

101 Hospital Boulevard, 
Jeffersonville, IN 
 (0.1 miles away)
812-282-3899
Experience:
24+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Charles Goodwin is a Urologist practicing medicine in Jeffersonville, Indiana. He has been practicing medicine for over 24 years. Dr. Goodwin is highly rated in 52 conditions, according to our data. His clinical expertise encompasses UPJ Obstruction, Kidney Stones, Bilateral Hydronephrosis, Ureteroscopy, and Reconstructive Urology Surgery. Dr. Goodwin is board certified in American Board Of Urology, Urology - 2010. Dr. Goodwin is currently accepting new patients.

Expertise in
50
conditions
Expertise in
50
conditions
Referral may be required

First Urology PSC

101 Hospital Blvd, 
Jeffersonville, IN 
 (0.1 miles away)
812-282-3899
Languages Spoken:
English
See accepted insurances

Dennis Smith is a Urologist practicing medicine in Jeffersonville, Indiana. Dr. Smith is highly rated in 50 conditions, according to our data. His clinical expertise encompasses Hydronephrosis, UPJ Obstruction, Bilateral Hydronephrosis, Ureteroscopy, and Reconstructive Urology Surgery.

Frequently Asked Questions about Dr. James Bailen

How do I make an appointment with Dr. James Bailen?

You can book an appointment with Dr. James Bailen by calling their office at 502-585-1016. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. James Bailen a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. James Bailen is classified as an Distinguished expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. James Bailen specialize in?

While Dr. James Bailen is a Urology, they have specific expertise in Prostate Cancer, Familial Prostate Cancer, and Bladder Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Urology.

Does Dr. James Bailen participate in research or clinical trials?

Yes. Dr. James Bailen has published 14 articles and abstracts on conditions like Prostate Cancer. You can view a list of Dr. James Bailen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. James Bailen accept my insurance?

Dr. James Bailen accepts most major insurance plans, including Anthem BCBS and CareSource. We recommend calling the office directly at 502-585-1016 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bailen's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile